[ad_1]
Arcus Biosciences RCUS reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:03 PM.
Here’s what investors need to know about the announcement.
Earnings
Arcus Biosciences beat estimated earnings by 1.06%, reporting an EPS of $-0.93 versus an estimate of $-0.94.
Revenue was up $17.30 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.65 which was followed by a 11.67% increase in the share price the next day.
Here’s a look at Arcus Biosciences’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.31 | -0.74 | -1.08 | -0.88 |
| EPS Actual | -0.96 | 3.71 | -1.11 | -1.09 |
| Revenue Estimate | 79.42M | 39.39M | 9.40M | 13.05M |
| Revenue Actual | 18.00M | 354.50M | 9.46M | 9.46M |
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.31 | -0.74 | -1.08 | -0.88 |
| EPS Actual | -0.96 | 3.71 | -1.11 | -1.09 |
| Revenue Estimate | 79.42M | 39.39M | 9.40M | 13.05M |
| Revenue Actual | 18.00M | 354.50M | 9.46M | 9.46M |
To track all earnings releases for Arcus Biosciences visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
[ad_2]
Image and article originally from www.benzinga.com. Read the original article here.